DEVON BRIGGS: Open Payments
NPI 1649259714 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$632 in 18 payments from 7 companies in 2025. Trend: 2023 $346 · 2024 $582 · 2025 $632
Food & beverage: $626Education: $5
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 2 | $253 |
| Teva Pharmaceuticals USA, Inc. | 5 | $121 |
| E.R. Squibb & Sons, L.L.C. | 3 | $77 |
| Otsuka America Pharmaceutical, Inc. | 3 | $62 |
| Lundbeck LLC | 2 | $52 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $38 |
| Alkermes, Inc. | 1 | $29 |
Products named: INVEGA SUSTENNA, UZEDY, COBENFY, ABILIFY MAINTENA, CAPLYTA, ARISTADA, ABILIFY ASIMTUFII, REXULTI.
Industry payments across GA — which companies pay providers there.
